



# 2021 Quality Payment Program (QPP) Measure Specification and Measure Flow Guide for MIPS Clinical Quality Measures (CQMs)

Utilized by Merit-based Incentive Payment System (MIPS) Eligible Clinicians, Groups, or Third-Party Intermediaries

November 2020

# Introduction

This document contains general guidance for the 2021 Quality Payment Program (QPP) Individual Measure Specifications and Measure Flows for MIPS clinical quality measures (CQMs) submissions. The individual measure specifications are detailed descriptions of the quality measures and are intended to be utilized by individual MIPS eligible clinicians submitting CQMs via Quality Clinical Data Registry (QCDR) or Qualified Registries and by groups submitting via Qualified Registry for the 2021 QPP. In addition, each measure specification document includes a measure flow and associated algorithm as a resource for the application of logic for data completeness and performance. Please note that the measure flows were created by CMS and may or may not have been reviewed by the Measure Steward. These diagrams should not be used in place of the measure specification but may be used as an additional resource.

### **Collection Types**

Data submission from individual CQMs may be collected by individual MIPS eligible clinicians or groups. Other collection types will utilize different submission types as outlined below.

- There are separate documents for Medicare Part B claims measures collection type.
- Groups electing to submit via the Web Interface (WI) should utilize the Web Interface Measure documents.
- Measure specifications for electronic health record (EHR) based submission should be utilized for the electronic clinical quality measures (eCQMs).
- Information regarding CG-CAHPS may be found at: <a href="https://www.ahrq.gov/cahps/about-cahps/index.html">https://www.ahrq.gov/cahps/about-cahps/index.html</a>

# Clinical Quality Measures Specifications

Each measure is assigned a unique number. Measure numbers for 2021 QPP represent a continuation in numbering from the 2020 QPP measures. Measure stewards have provided revisions for the measures that are finalized for use in 2021 QPP.

### **Frequency with Definitions**

Frequency labels are provided in each measure instruction as well as the measure flow. The analytical submitting frequency defines the time period or event for which the measure should be submitted. Each individual MIPS eligible clinician participating in 2021 QPP should submit during the performance period according to the frequency defined for the measure. Below are definitions of the analytical submitting frequencies that are utilized for calculations of the individual measures:

- Patient-Intermediate measures are submitted a minimum of once per patient during the performance period. The most recent quality-data code will be used, if the measure is submitted more than once.
- Patient-Process measures are submitted a minimum of once per patient during the performance period. The most advantageous quality-data code will be used if the measure is submitted more than once.
- Patient-Periodic measures are submitted a minimum of once per patient per timeframe specified by the
  measure during the performance period. The most advantageous quality-data code will be used if the measure
  is submitted more than once. If more than one quality-data code is submitted during the episode time period,
  performance rates shall be calculated by the most advantageous quality-data code.
- **Episode** measures are submitted once for each occurrence of a particular illness or condition during the performance period.
- **Procedure** measures are submitted each time a procedure is performed during the performance period.
- **Visit** measures are submitted each time a patient is seen by the individual MIPS eligible clinician during the performance period.

### **Performance Period**

There are several sections (Instruction, Description, or Numerator Statement) within the measure specification that may include information on the performance period. Performance period for the measure may refer to the calendar year of January 1st to December 31st. However, measures may have a different timeframe for determining if the quality action indicated within the measure was performed. This may be referenced as the measurement period. For example, in Quality ID # 19 (NQF 0089): Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care the submitting MIPS eligible clinician would be allowed to 'look back' from the date of the denominator eligible encounter and 'forward' to the end of the current program year to confirm if the most advantageous numerator option was met.

### **Denominator and Numerator**

Quality measures consist of a numerator and denominator that are used to calculate data completeness and performance for a defined patient population. These calculations indicate either achievement of a particular process of care being provided or a clinical outcome being attained. The denominator is the lower part of a fraction used to calculate a rate, proportion, or ratio. The numerator is the upper portion of a fraction used to calculate a rate, proportion, or ratio and represents a subset of the denominator population.

The numerator represents the target quality actions defined within the measure. It may be a process, condition, event, or outcome. Numerator criteria are the measure defined quality actions expected for each patient, procedure, or other unit of measurement defined in the denominator.

### **Denominator Codes (Eligible Cases)**

The denominator population is specified in the measure and submitted by individual MIPS eligible clinicians, groups, or third-party intermediaries. The denominator population may be defined by the following criteria:

- Demographic information
- International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis,
- International Classification of Diseases, Tenth Revision Procedure Coding System (ICD-10-PCS)
- Current Procedural Terminology (CPT)
- Healthcare Common Procedure Coding System (HCPCS) codes

The CQM collection type may include patients from all payers not just Medicare Part B Physician Fee Schedule (PFS) covered services. HCPCS coding may include G-codes, D-codes, S-codes, or M-codes. These HCPCS codes may be found in the denominator and would be associated with billable charges. These QDC's describe clinical outcomes that assist with determining the intended population.

If the specified denominator codes for a measure are not applicable to the patient (for the same date of service) as submitted by the individual MIPS eligible clinician, group, or third-party intermediary, then the patient does not fall into the measure's eligible denominator. Some measure specifications are adapted as needed during the annual update process for implementation in agreement with the measure steward.

Measure specifications include specific instructions regarding CPT Category I modifiers, place of service codes (POS), and other detailed information. Each MIPS eligible clinician, group, or third-party intermediary should carefully review the measure's denominator coding to determine whether codes submitted to a Qualified Registry or QCDR meet denominator inclusion criteria.

Denominator exclusions describe a circumstance where the patient should be removed from the denominator. Measure specifications define denominator exclusion(s) in which a patient should not be included in the intended population for the measure even if other denominator criteria are applicable. Quality-data codes (QDCs) or equivalent codes are available to describe the denominator exclusion and are provided within the measure specification. Patients that meet the intent of the denominator exclusion do not need to be included for data completeness or in the performance rate of the measure.

### **Numerator Quality-Data Codes**

If the patient does fall into the denominator population and no denominator exclusions apply, the applicable QDCs or equivalent as indicated by the registry that define the numerator options should be submitted for data completeness of quality data for CQM submissions.

### **Performance Met**

If the intended quality action for the measure is performed for the patient, QDCs or equivalent from the CQM are available to describe that performance has been met and should be submitted to the Qualified Registry or QCDR.

### **Denominator Exception**

When a patient falls into the denominator, but the measure specifications define circumstances in which a patient may be appropriately deemed as a denominator exception. CPT Category II code modifiers such as 1P, 2P, and 3P, QDCs, or equivalents referenced in the CQM are available to describe medical, patient or system reasons for denominator exceptions and can be submitted to the Qualified Registry or QCDR. A denominator exception removes a patient from the performance denominator only if the numerator criteria are not met as defined by the exception. This allows for the exercise of clinical judgement by the MIPS eligible clinician.

### Performance Not Met

When the denominator exception does not apply, a measure-specific CPT Category II submitting modifier 8P, QDC, or equivalent in the CQM may be used to indicate that the quality action was not provided for a reason not otherwise specified and should be submitted to the Qualified Registry or QCDR.

### **Inverse Measure**

A lower calculated performance rate for this type of measure would indicate better clinical care or control. The "Performance Not Met" numerator option for an inverse measure is the representation of the better clinical quality or control. Submitting that numerator option will produce a performance rate that trends closer to 0%, as quality increases. For inverse measures a rate of 100% means all of the denominator eligible patients did not receive the appropriate care or were not in proper control.

Each measure specification provides detailed Numerator Options for submitting on the quality action described by the measure. The numerator clinical concepts described for each measure are to be followed when submitting data to a Qualified Registry or QCDR.

QDCs may be found in the numerator and may utilize HCPCS coding. These QDCs describe quality actions that assist with determining the numerator outcome.

### **Clinical Quality Measure Collection Type**

For MIPS eligible clinicians submitting individually, measures (including patient-level measure[s]) may be submitted for the same patient by multiple MIPS eligible clinicians practicing under the same Tax Identification Number (TIN). If a patient sees multiple providers during the performance period, that patient can be counted for each individual NPI submitting if the patient meets denominator inclusion. The following is an example of two provider NPIs (National Provider Identifiers), billing under the same TIN who are intending to submit Quality ID # 130 (NQF 0419): Documentation of Current Medications in the Medical Record. Provider A sees a patient on February 2, 2021 and documents in the medical record that they obtained, updated, or reviewed the patient's current medications and submits the appropriate QDC, G8427, for Quality ID # 130. Provider B sees the same patient at an encounter on July 16, 2021 and documents in the medical record that they obtained, updated, or reviewed the patient's current medications. Provider B should also submit the appropriate QDC's for the patient at the July encounter to meet data completeness for submission of Quality ID # 130.

## **Group Submission**

MIPS eligible clinicians submitting under a group practice selecting to participate in the group submission under the

same Tax Identification Number (TIN), should be submitting on the same patient, when instructed within the chosen measure. For example, if submitting Quality ID # 130 (NQF 0419): Documentation of Current Medications in the Medical Record all MIPS eligible clinicians under the same TIN would submit each denominator eligible instance as instructed by this measure.

If the group choses a measure that is required to be submitted once per performance period, then this measure should be submitted at least once during the measure period by at least one MIPS eligible clinician under the TIN. Quality ID # 6: Coronary Artery Disease (CAD): Antiplatelet Therapy is an example of a measure that would be submitted once per performance period under the TIN.

CMS recommends review of any measures that an individual MIPS eligible clinician or group intends to submit. Below is an example measure specification that will assist with data completeness for a measure. For additional assistance, please contact the Service Now help desk at 1- 866-288-8912 (Monday – Friday 8:00AM – 8:00PM Eastern Time) or email via <a href="mailto:qnetsupport@hcqis.org">qnetsupport@hcqis.org</a>.

### Clinical Quality Measure Specification Format (Refer to the Example CQM Specification Below)

Quality ID number, National Quality Forum (NQF) number (if applicable), measure title, National Quality Strategy Domain, and Meaningful Measure Area

Collection type

Measure type

Measure description

Instructions on submitting including frequency, timeframes, and applicability

Denominator statement, denominator criteria, coding, and denominator exclusion

Numerator statement and coding options (performance met, denominator exception, performance not met)


Definition(s) of terms where applicable

Rationale

Clinical recommendations statement or clinical evidence supporting the measure intent

The Rationale and Clinical Recommendation Statements sections provide limited clinical guidelines and supporting clinical references regarding the quality actions described in the measure. Please contact the Measure Steward for section references and further information regarding the clinical rationale and recommendations for the described quality action. Measure Steward contact information is located on the last tab of the 2021 MIPS Quality Measures List, which can be found on the MIPS Explore Measures page: https://gpp.cms.gov/mips/explore-measures.

### **Example Clinical Quality Measure (CQM) Specification:**



This segment includes a highlevel description of the measure.

This details how often the measure should be submitted and who should submit the measure.

This will identify whether a measure is eligible for telehealth.

The denominator statement describes the population evaluated by the performance measure.

Review patient demographics. diagnoses and encounter coding to determine if the patient meets denominator criteria. Fach denominator criterion is required in order for the patient to be considered denominator eligible for submission. Helpful Hint: Some OPP measures have similar denominator criteria or encounter type coding.

### INSTRUCTIONS:

This measure is to be submitted a minimum of <u>once per measurement period</u> for patients seen during the measurement period. The most recent quality-data code submitted will be used for performance calculation. This measure may be submitted by Merit-based Incentive Payment System (MIPS) eligible clinicians who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding. The follow-up plan must be related to a positive depression screening, example: "Patient referred for psychiatric evaluation due to positive depression screening".

NOTE: Patient encounters for this measure conducted via telehealth (e.g., encounters coded with GQ, GT, 95, or POS 02 modifiers) are allowable.

### Measure Submission Type:

Measure data may be submitted by individual MIPS eligible clinicians, groups, or <a href="https://doi.org/10.10/10/2016/bit.2016/

### DENOMINATOR:

All patients aged 12 years and older at the beginning of the measurement period with at least one eligible encounter during the measurement period

### Definition:

Not Eligible for Depression Screening or Follow-Up Plan (Denominator Exclusion) -

- Patients who have been diagnosed with depression- F01.51, F32.0, F32.1, F32.2, F32.3, F32.4, F32.5, F32.89, F32.9, F33.0, F33.1, F33.2, F33.3, F33.40, F33.41, F33.42, F33.8, F33.9, F34.1, F34.81, F34.89, F43.21, F43.23, F53.0, F53.1, O90.6, O99.340, O99.341, O99.342, O99.343, O99.345
- Patients who have been diagnosed with bipolar disorder- F31.10, F31.11, F31.12, F31.13, F31.2,
   F31.30, F31.31, F31.32, F31.4, F31.5, F31.60, F31.61, F31.62, F31.63, F31.64, F31.70, F31.71,
   F31.72, F31.73, F31.74, F31.75, F31.76, F31.77, F31.78, F31.81, F31.89, F31.9

**DENOMINATOR NOTE:** The intent of the measure is to screen for depression in patients who have never had a diagnosis of depression or bipolar disorder prior to the eligible encounter used to evaluate the numerator. Patients who have ever been diagnosed with depression or bipolar disorder will be excluded from

6

Version 5.0 November 2020 CPT only copyright 2020 American Medical Association. All rights reserved.
Page 1 of 11

the measure.

Me asures may contain denominator exclusions within the denominator. Denominator exclusions are used to narrow the me asure population before determining if the quality action is met.

\*Signifies that this CPT Category I code is a non-cover Schedule (PFS). These non-covered services should be COMe

### Denominator Criteria (Eligible Cases):

These are the criteria to determine if the patient. procedure, or encounter may be counted as eligible to meet a measure's inclusion requirements. The denominator requirements reflect the intent of the me asure.

Patient encounter during the performance period (CPT or HCPCS): 59400, 59510, 59610, 59618, 90791.

90792, 90832, 90834, 90837, 92625, 96105, 96110, 96112, 96116, 9612 97162, 97163, 97165, 97166, 97167, 99078, 99202, 99203, 99204, 99205 99305, 99306, 99307, 99308, 99309, 99310, 99315, 99316, 99318, 99326, 99336, 99 99386\*, 99387\*, 99394\*, 99395\*, 99396\*, 99397\*, G0101, G0402, G0438

The denominator is generally identified by CPT Category I and HCPCS codes, as well as ICD-10CM or PCS codes, patient demographics (i.e. age, gender, etc.), and place of service (if applicable).

# AND NOT DENOMINATOR EXCLUSION:

Documentation stating the patient has had a diagnosis of depression or has had a diagnosis of bipolar disorder: G9717

### NUMERATOR: <

Patients screened for depression on the date of the encount using an age-appropriate standardized tool AND if positive, a eligible encounter

This is a clinical action counted as meeting the me asure's requirements (i.e. a patient who received a particular clinical service or obtained a particular outcome that is being measured).

Definitions. provide further information on the intent of key concepts to assist with me asure submission.

#### Definitions:

Screening - Completion of a clinical or diagnostic tool used to identify people at risk of developing or having a certain disease or condition, even in the absence of symptoms.

Standardized Depression Screening Tool - A normalized and validated depression screening tool developed for the patient population in which it is being utilized...

Examples of standardized depression screening tools include but are not limited to:

Adolescent Screening Tools (12-17 years)
Patient Health Questionnaire for Adolescents (PHQ-A), Beck Depression Inventory-Primary Care
Version (BDI-PC), Mood Feeling Questionnaire (MFQ), Center for Epidemiologic Studies Depression
Scale (CES-D), Patient Health Questionnaire (PHQ-9), Pediatric Symptom Checklist (PSC-17), and PRIME MD-PHQ-2

Adult Screening Tools (18 years and older)

Patient Health Questionnaire (PHQ-9), Beck Depression Inventory (BDI or BDI-II), Center for Epidemiologic Studies Depre PEPS), Duke Anxiety-Depression Scale (DADS), G Dementia (CSDD), PRIME M This is an example of a cale for Depression in complex Numerator. Review ession (HAM-D), Quick Inventory of Depressive Sym the Numerator section terized Adaptive Testing Depression Inventory (CAT-I carefully to submit the quality-Screener (CAD-MDD) data codes (QDC's)

necessary to meet data

completeness and

performance.

Perinatal Screening Tools Edinburgh Postnatal Depres Questionnaire 9 (PHQ-9), Be Epidemiologic Studies Depre Follow-Up Plan - Documented follow

ing Scale, Patient Health Inventory-II, Center for on Scale st include one or more of the

following: Referral to a practitioner who is qualified to diagnose and treat depression

Pharmacological interventions

Version 5.0 November 2020 CPT only copyright 2020 American Medical Association. All rights reserved. Page 2 of 11

- Other interventions or follow-up for the diagnosis or treatment of depression
- Examples of a follow-up plan include but are not limited to:
- . Referral to a practitioner or program for further evaluation for depression, for example, referral to a psychiatrist, psychologist, social worker, mental health counselor, or other mental health service such as family or group therapy, support group, depression management program, or other service for treatment of depression
- Other interventions designed to treat depression such as behavioral health evaluation, psychotherapy, pharmacological interventions, or additional treatment options

Patients with a Documented Reason for not Screening for Depression (Denominator Exception) -Patient Reason(s)

Patient refuses to participate

OR

### Medical Reason(s)

Documentation of medical reason for not screening patient for depression (e.g., cognitive, functional, or motivational limitations that may impact accuracy of results; patient is in an urgent or emergent situation where time is of the essence and to delay treatment would jeopardize the patient's health status)

### Numerator Instructions:

A depression screen is completed on the date of the encounter or up to 14 days prior to the date of the encounter using an age-appropriate standardized depression screening tool AND if positive, a follow-up plan must be documented on the date of the encounter, such as referral to a practitioner who is qualified to treat depression, pharmacological interventions or other interventions for the treatment of depression.

Depression screening is required once per measurement period, not at all encounters. An age-appropriate, standardized, and validated depression screening tool must be used for numerator compliance. The name of the age-appropriate standardized depression screening tool utilized must be documented in the medical record. The depression screening must be reviewed and addressed in the office of the provider on the date of the encounter. Positive pre-screening results indicating a patient is at high risk for self-harm should receive more urgent intervention as determined by the provider practice. The screening should occur during a qualifying encounter or up to 14 days prior to the date of the qualifying encounter.

The measure assesses the most recent depression screening completed either during the eligible encounter or within the 14 days prior to that encounter. Therefore, a clinician would not be able to complete another screening at the time of the encounter to count towards a follow-up, because that would serve as the most recent screening. In order to satisfy the follow-up requirement for a patient screening positively, the eligible clinician would need to provide one of the aforementioned follow-up actions, which does not include use of a standardized depression screening tool.

Should a patient screen positive for depression, a clinician should opt to complete a suicide risk assessment when appropriate and based on individual patient characteristics. However, for the purposes of this measure, a suicide risk assessment or additional screening using a standardized tool, will not qualify as a follow-up plan.

Section 1: Data Completeness and Performance Met OR

**Numerator Options:** Performance Met:

Performance Met:

Screening for depression is documented as being positive AND a follow-up plan is documented (G8431)

Screening for depression is documented as negative, a follow-up plan is not required (G8510)

Version 5.0 November 2020 CPT only copyright 2020 American Medical Association. All rights reserved

#### Section 2:

Measures may have denominator exceptions to represent a medical (1P), patient (2P), or system (3P) reasons for not performing the quality action. Some measures within Quality Payment Program allow no denominator exceptions.

Denominator Exception:

Screening for depression not completed, documented reason (G8433)

Section 3: Data Completeness and Performance not

Performance Not Met:

OR Performance Not Met: Depression screening not documented, reason not given (G8432)

Screening for depression documented as positive, followup plan not documented, reason not given (G8511)

### RATIONALE:

<u>OR</u>

This is a brief statement describing the evidence base and/or intent for the measure. Depression is a serious medical illness associated with higher rates of chronic disease, increased has and impaired functioning (Katon, 2003; Wells et al., 1989). 2016 U.S. survey data indicate (3.1 million adolescents) had a major depressive episode (MDE) in the past year, with nin million adolescents) having one MDE with severe impairment. The same data indicate that older (16.2 million adults) had at least one MDE with 4.3 percent of adults (10.3 million ad severe impairment in the past year (Substance Abuse and Mental Health Services Administrates of the past year (Substance Abuse and Mental Health Services Administrates of the past year (Substance Abuse and Mental Health Services Administrates of the past year (Substance Abuse and Mental Health Services Administrates of the past year (Substance Abuse and Mental Health Services Administrates of the past year (Substance Abuse and Mental Health Services Administrates of the past year (Substance Abuse and Mental Health Services Administrates of the past year (Substance Abuse and Mental Health Services Administrates of the past year (Substance Abuse and Mental Health Services Administrates of the past year (Substance Abuse and Mental Health Services Administrates of the past year (Substance Abuse and Mental Health Services Administrates of the past year (Substance Abuse and Mental Health Services Administrates of the past year (Substance Abuse and Mental Health Services Administrates of the past year (Substance Abuse and Mental Health Services Administrates of the past year (Substance Abuse and Mental Health Services Administrates of the past year (Substance Abuse and Mental Health Services Administrates of the past year (Substance Abuse and Mental Health Services Administrates of the past year (Substance Abuse and Mental Health Services Administrates of the past year (Substance Abuse and Mental Health Services Administrates of the past year (Substance Abuse and Mental Health Services Administrates of the past year (Substance Abuse and Mental Health Services Ad

These codes are examples of QDC's or Quality Data Codes. These codes may be used to identify numerator options.

severity of depressive symptoms increased, rates of having difficulty with work, home, or social activities related to depressive symptoms increased. For those twelve and older with mild depressive symptoms, 45.7% reported difficulty with activities and those with severe depressive symptoms, 88.0% reported difficulty (Pratt & Brody, 2014). Children and teens with major depressive disorder (MDD) have been found to have difficulty carrying out their daily activities, relating to others, growing up healthy, and also are at an increased risk of suicide (Siu on behalf of the U.S. Preventive Services Task Force [USPSTF], 2016). Additionally, perinatal depression (considered here as depression arising in the period from conception to the end of the first postnatal year) affects up to 12% of women (Woody, Ferrari, Siskind, Whiteford, & Hamis, 2017). Depression and other mood disorders, such as bipolar disorder and anxiety disorders, especially during the perinatal period, can have devastating effects on women, infants, and families (American College of Obstetricians and Gynecologists, 2018). Maternal suicide rates rise over hemorrhage and hypertensive disorders as a cause of maternal mortality (Palladino, Singh, Campbell, Flynn, & Gold, 2011).

Negative outcomes associated with depression make it crucial to screen in order to identify and treat depression in its early stages. While Primary Care Providers (PCPs) serve as the first line of defense in the detection of depression, studies show that PCPs fail to recognize up to 50% of depressed patients (Borner, Braunstein, St. Victor, & Pollack, 2010). "In nationally representative U.S. surveys, about eight percent of adolescents reported having major depression in the past year. Only 36% to 44% of children and adolescents with depression receive treatment, suggesting that the majority of depressed youth are undiagnosed and untreated" (Siu on behalf of USPSTF, 2016, p. 360 & p. 364). Evidence supports that screening for depression in pregnant and postpartum women is of moderate net benefit and treatment options for positive depression screening should be available for patients twelve and older including pregnant and postpartum women.

If preventing negative patient outcomes is not enough, the substantial economic burden of depression for individuals and society alike makes a case for screening for depression on a regular basis. Depression imposes economic burden through direct and indirect costs: "In the United States, an estimated \$22.8 billion was spent on depression treatment in 2009, and lost productivity cost an additional estimated \$23 billion in 2011" (Siu & USPSTF, 2016, p. 383-384).

This measure seeks to align with clinical guideline recommendations as well as the Healthy People 2020 recommendation for routine screening for mental health problems as a part of primary care for both children and adults (U.S. Department of Health and Human Services, 2014) and makes an important contribution to the quality domain of community and population health.

CLINICAL RECOMMENDATION STATEMENTS: 
Adolescent Recommendation (12-18 years):

This is a summary of the clinical recommendations based on best practices.

"The USPSTF recommends screening for MDD in adolescents aged 12 to 18 years. Screening should be

Version 5.0 November 2020 CPT only copyright 2020 American Medical Association. All rights reserved. Page 4 of 11

implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up (B recommendation)" (Siu on behalf of USPSTF, 2016, p. 360).

Adult Recommendation (18 years and older)

"The USPSTF recommends screening for depression in the general adult population, including pregnant and postpartum women. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up (8 recommendation)" (Siu & USPSTF, 2016, p. 380).

The Institute for Clinical Systems Improvement (ICSI) health care guideline, Adult Depression in Primary Care, provides the following recommendations:

- 1. "Clinicians should routinely screen all adults for depression using a standardized instrument."
- 2. "Clinicians should establish and maintain follow-up with patients."
- "Clinicians should screen and monitor depression in pregnant and post-partum women." (Trangle et al., 2016 p.. 8 10).

This is the copyright for the measure as indicated by the measure steward.

COPYRIGHT: <

These performance measures are not clinical guidelines and do not establish a standard of medical care, and have not been tested for all potential applications.

### THE MEASURES AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND.

Limited proprietary coding is contained in the measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. PCPI disclaims all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.

CPT® contained in the Measure specifications is copyright 2004-2020 American Medical Association. LOINC® is copyright 2004-2020 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms® (SNOMED CT®) copyright 2004-2020 International Health Terminology Standards Development Organisation. ICD-10 is copyright 2020 World Health Organization. All Rights Reserved.

Version 5.0 November 2020 CPT only copyright 2020 American Medical Association. All rights reserved.


Page 5 of 11

# **Interpretation of Clinical Quality Measure Flows**


# **Denominator**

The CQM Flows are designed to provide interpretation of the measure logic and calculation methodology for data completeness and performance rates. The flows start with the identification of the patient population (denominator) for the applicable measure's quality action (numerator). When determining the denominator for all measures, please remember to include patients from all payers and CPT Categories **without** modifiers 80, 81, 82, AS or TC.


Below is an illustration of the above prerequisite denominator criteria to obtain the patient sample for all 2021 CQMs:




The CQM Flows in each specification document begin with the appropriate age group and denominator population for the measure. The Eligible Population box equates to the letter "d" by the patient population that meets the measures inclusion requirements. Below is an example of the denominator criteria used to determine the eligible population for Quality ID # 6: Coronary Artery Disease (CAD): Antiplatelet Therapy:



In some instances denominator exclusions will be found within the denominator. Quality ID # 134: Preventive Care and Screening: Screening for Depression and Follow-Up Plan Rate below is an example of a measure that exhibits a denominator exclusion that is labeled and is represented by a purple diamond.




Some measures, such as Quality ID # 5 (NQF 0081): Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD), have multiple options to determine the measure's denominator. Patients meeting the submission criteria for either denominator option are included as part of the eligible population. Review the CQM to determine if multiple performance rates are required for each submission criteria.




Some CQMs, such as Quality ID # 226 (NQF 0028) Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention have multiple submission criteria and multiple performance rates. Patients meeting the criteria for either denominator option are included as part of the eligible population. Review the CQM to determine if multiple performance rates are required for each submission criteria.

# Submission Criteria One/ All patients who were screened for tobacco use


Submission Criteria Two/ All patients who were identified as a tobacco user and who received tobacco cessation intervention





### **Numerator**

Once the denominator is identified, the flow illustrates and stratifies the quality action (numerator) for data completeness. Depending on the measure, there are several outcomes that may be applicable for submitting the measures outcome: Top right box - Performance Met = "a" and shaded green; Middle right boxes - Denominator Exception = "b" and shaded yellow; bottom box - Performance Not Met = "c" and shaded gray; and bottom left box - Data Completeness Not Met = shaded red. On the flow, these outcomes are color-coded and labeled to identify the particular outcome of the measure represented. This is illustrated below for Quality ID # 6: Coronary Artery Disease (CAD): Antiplatelet Therapy:



### Denominator/Numerator Variation of Medicare Part B claims vs. CQM Collection Types

For measures submitted via Medicare Part B claims or CQM, there are separate Measure Specifications, Flows, and Narratives. The denominator for the CQM measure may differ slightly from the denominator as outlined in the Medicare Part B claims measure specification. Some measures, such as Quality ID # 19 Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care, have a clarifying code and/or language (e.g. G-code G8397 for Quality ID # 19) in the numerator to identify eligible patients when no CPT or ICD-10 diagnosis code exists. In the case of Quality ID # 19, an applicable CPT code does not exist for dilated macular or fundus exam performed, including documentation of the presence or absence of macular edema AND level of severity of retinopathy. In Medicare Part B claims collection type, a MIPS eligible clinician would submit the numerator code G8397 to identify patients who had a dilated macular or fundus exam with documentation of the results. To comply with the Measure Steward's intent of the measures and since Qualified Registries or QCDRs may not necessarily be reliant on Medicare Part B claims data; the CQM collection type measure specification and flow show these QDCs or clinical concepts in the denominator. Therefore, the numerator quality-data code options for CQM specifications and flow may vary from the Medicare Part-B claims measure specification and flow.

# **Algorithms**

### **Data Completeness Algorithm**

The Data Completeness Algorithm calculation is based on the eligible population and sample outcomes of the possible quality actions as described in the flow of the measure. The Data Completeness Algorithm provides the calculation logic for patients who have been submitted in the MIPS eligible clinicians' appropriate denominator. Data completeness for a measure may include the following categories provided in the numerator: Performance Met, Denominator Exception, and Performance Not Met. Below is a sample data completeness algorithm for Quality ID # 6. In the example, 80 patients met the denominator criteria for eligibility, where 40 patients had the quality action performed (Performance Met), 10 patients did not receive the quality action for a documented reason (Denominator Exception), and 20 patients were reported as not receiving the quality action (Performance Not Met). **Note**: In the example, 10 patients were eligible for the measure but were not submitted and are not represented in the algorithm (Data Completeness Not Met). Additionally, depending on the Qualified Registry's or QCDR's data source and abstraction method, the data completeness may not reflect missing numerator data.

### Data Completeness =

 $\frac{\text{Performance Met (a=40 patients) + Denominator Exception (b1+b2+b3=10 patients) + Performance Not Met (c=20 patients)}}{\text{Eligible Population/Denominator (d=80 patients)}} = \frac{70 \text{ patients}}{80 \text{ patients}} = 87.50\%$ 

### **Performance Algorithm**

The Performance Algorithm calculation begins with only those patients where data completeness was met and reported for the measure. For those patients reported, the numerator is then determined based on completion of the quality action as indicated by Performance Met. Meeting the quality action for a patient, as indicated in the CQM measure specification, would add one patient to the denominator and one to the numerator. Patients reporting with Denominator Exceptions are subtracted from the performance denominator when calculating the performance rate percentage. Below is a sample performance rate algorithm that represents this calculation for Quality ID # 6. In this scenario, the patient sample for data completeness per the numerator equals 70 patients where 40 of these patients had the quality action performed (Performance Met) and 10 patients were reported as having a Denominator Exception.

### Performance Rate=

 $\frac{\text{Performance Met(a=40 patients)}}{\text{Data Completeness Numerator (70 patients)} - \text{Denominator Exception(b}^1 + \text{b}^2 + \text{b}^3 = 10 \text{patients}} = \frac{40 \text{ patients}}{60 \text{ patients}} = 66.67\%$ 

For measures with inverse performance rates, such as Quality ID # 331: Adult Sinusitis: Antibiotic Prescribed for Acute Viral Sinusitis (Overuse), a lower rate indicates better performance. Submitting the Performance Not Met is actually the clinically recommended outcome or quality action.

# **Multiple Performance Rates**

QPP measures may contain multiple performance rates. The Instructions section of the CQM will provide guidance if the measure is indeed a multiple performance. The CQM flow for these measures includes algorithm examples to understand the different data completeness and performance rates required for the measure. Please note, only the performance rates outlined in the measure specification are to be submitted for CQM submissions. CMS, with Measure Steward feedback, will calculate an overall performance rate for the measure if none is specified within the measure.